Patents Assigned to Pharmagenics, Incs
  • Sequence specific DNA binding p53
    Patent number: 6245515
    Abstract: Specific sequences in the human genome are the sites of strong binding of wild-type p53 protein, but not mutant forms of the protein. These sequences are used diagnostically to detect cells in which the amount of wild-type p53 is diminished. The sequences can also be used to screen for agents which correct for loss of wild-type p53 to DNA in cancer cells.
    Type: Grant
    Filed: September 21, 1999
    Date of Patent: June 12, 2001
    Assignees: The Johns Hopkins University, Pharmagenics, Incs
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Michael I. Sherman
  • Reiterative method for screening combinatorial libraries
    Patent number: 5670326
    Abstract: Libraries of compounds such as nucleic acids or peptides are contacted with a target molecule and libraries that have at least one compound that bind with at least a minimum activity are determined by a reiterative process in which a change in the rate of recovery (elimination) of compounds that bind to the target indicates that the library contains such a compound. The procedure may also be used to determine indirectly the sequence of such compound by employing sublibraries, each of which have a known entity at a known position of the compound.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 23, 1997
    Assignee: PharmaGenics, Inc.
    Inventor: Bruce A. Beutel
  • Inhibition of interferon-.gamma. with oligonucleotides
    Patent number: 5599917
    Abstract: Oligonucleotides and analogs thereof that bind to and preferably modulate the activity of interferon-.gamma., and methods for their use, including therapeutic and diagnostic methods are disclosed.
    Type: Grant
    Filed: March 17, 1994
    Date of Patent: February 4, 1997
    Assignee: PharmaGenics, Inc.
    Inventors: George R. Coppola, Bruce A. Beutel, Arthur H. Bertelsen
  • Sequence specific DNA binding by p53
    Patent number: 5362623
    Abstract: Specific sequences in the human genome are the sites of strong binding of wild-type p53 protein, but not mutant forms of the protein. These sequences are used diagnostically to detect cells in which the amount of wild-type p53 is diminished. The sequences can also be used to screen for agents which correct for loss of wild-type p53 to DNA in cancer cells.
    Type: Grant
    Filed: March 31, 1992
    Date of Patent: November 8, 1994
    Assignees: The John Hopkins University, PharmaGenics, Inc.
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Michael I. Sherman